Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| CREATE Medicines | 2026 | Series B | Undisclosed | Cambridge |
| Moleculent | 2026 | Series A | $26.0M | Solna |
| Maze Therapeutics | 2026 | Post-IPO Equity | Undisclosed | South San Francisco |
| Lightcast Discovery | 2026 | Venture - Series Unknown | Undisclosed | Cambridge |
| Seaport Therapeutics | 2026 | Grant | $15.0M | Boston |
| Kardigan | 2025 | Series B | $254.0M | South San Francisco |
| Ollin Biosciences | 2025 | Series A | $100.0M | Austin |
| Dewpoint Therapeutics | 2025 | Series D | $59.1M | Boston |
| Treeline Biosciences | 2025 | Series A | $200.0M | Watertown |
| Tenvie Therapeutics | 2025 | Series A | $200.0M | South San Francisco |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 1 | CREATE Medicines | Series B | Undisclosed | Cambridge, United States |
| 2 | Moleculent | Series A | $26.0M | Solna, Sweden |
| 3 | Maze Therapeutics | Post-IPO Equity | Undisclosed | South San Francisco, United States |
| 4 | Lightcast Discovery | Venture - Series Unknown | Undisclosed | Cambridge, United Kingdom |
| 5 | Seaport Therapeutics | Grant | $15.0M | Boston, United States |
| 6 | Kardigan | Series B | $254.0M | South San Francisco, United States |
| 7 | Ollin Biosciences | Series A | $100.0M | Austin, United States |
| 8 | Dewpoint Therapeutics | Series D | $59.1M | Boston, United States |
| 9 | Treeline Biosciences | Series A | $200.0M | Watertown, United States |
| 10 | Tenvie Therapeutics | Series A | $200.0M | South San Francisco, United States |
CREATE Medicines is a biotech company developing in vivo CAR therapies using mRNA-LNP immune cell programming technology.
Moleculent is the Biotechnology Research company.
Maze Therapeutics is a biotechnology company that develops precision medicines for renal, cardiovascular, and metabolic diseases.
Lightcast uses a microfluidic platform to make advances towards unique clinical approaches, new therapies, and innovative products.
Seaport Therapeutics is a clinical-stage biopharmaceutical company that develops neuropsychiatric medicines.
Kardigan develops personalized medicines using AI and data to target and treat the root causes of cardiovascular diseases.
Ollin Biosciences operates as a clinical-stage biopharmaceutical company.
Dewpoint Therapeutics is a biotech company developing a drug platform that targets biomolecular condensates.
Treeline Biosciences is a biotech company building transformative precision medicines for patients with cancer and other serious conditions.
Tenvie Therapeutics is a biotechnology company that transforms the treatment of neurological diseases through engineered small molecules.
Akamis Bio is a clinical-stage oncology company.
Bit.bio specializes in the fields of coding and biology that determine the identity of every human cell.
City Therapeutics is a biopharmaceutical company focused on developing next-generation small interfering RNAs.
Rippl Care is a mental health company committed to assisting seniors who suffer from dementia and other neurocognitive disorders.
Vilya is a biotechnology company developing a novel class of drugs that precisely target the biology of disease.
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
Over millions and millions of years, a collection of reward systems
Proniras focuses on development of a new parenteral medical countermeasure (MCM) to treat seizures and brain injury.
Basking Biosciences is to commercialize technology developed at Duke and Ohio State Universities.
Accompany Health provides comprehensive in-home care to patients who live in sometimes underserved regions.
Tome Biosciences is a biotechnology company that develops programmable gene insertion technology.
Magnet Biomedicine is a biotechnology research platform specializing in discovering true molecular glues.
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome.
OncoResponse is an immuno-oncology biotech company developing cancer immunotherapies leveraging human immune system responses.
Recuro Health offers a holistic suite of virtual care services and supplemental benefits.
ARCH Venture Partners has invested in 156 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
ARCH Venture Partners's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Life Science. The firm invests across 19 different industry categories.
Among tracked funding rounds, Kardigan received $254.0M in a Series B round. ARCH Venture Partners's total known invested capital is $14.3B.
ARCH Venture Partners's average investment size is $119.8M across its portfolio of 156 companies.
Recent ARCH Venture Partners portfolio additions include CREATE Medicines, Moleculent, Maze Therapeutics, Lightcast Discovery, Seaport Therapeutics. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors